<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
----------
SCHEDULE 13G/A
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b), (c) and (d) AND AMENDMENTS THERETO
FILED PURSUANT TO 13d-2
(Amendment No. 1) (1)
THERAPEUTIC ANTIBODIES INC.
- --------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK
- --------------------------------------------------------------------------------
(Title of Class of Securities)
88337M100
- --------------------------------------------------------------------------------
(CUSIP Number)
11 FEBRUARY 1999
- --------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
- ---------
(1) The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE> 2
Schedule 13G Forms
CUSIP No. 88337M100 13G Page 2 of 5 Pages
- -----------------------------------------------------------------------------
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
REPUBLIC OF SINGAPORE
- -----------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) / /
(b) /X/
- -----------------------------------------------------------------------------
3. SEC USE ONLY
- -----------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
SINGAPORE
- -----------------------------------------------------------------------------
5. SOLE VOTING POWER
NUMBER OF
SHARES 1,068,634
BENEFICIALLY ----------------------------------------------------------
OWNED BY 6. SHARED VOTING POWER
EACH
REPORTING NOT APPLICABLE
PERSON ----------------------------------------------------------
WITH 7. SOLE DISPOSITIVE POWER
1,068,634
----------------------------------------------------------
8. SHARED DISPOSITIVE POWER
NOT APPLICABLE
- -----------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,068,634
- -----------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* / /
- -----------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
2.05%
- -----------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON*
OTHER
- -----------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE> 3
Page 3 of 5
Item 1(a). Name of Issuer
Therapeutic Antibodies Inc
Item 1(b). Address of Issuers' Principal Executive Offices
1207 17th Avenue South
Suite 103 Nashville, TN37212
United States
Item 2(a). Name of Person Filing
Republic of Singapore
Item 2(b). Address of Principal Business Office
c/o Government of Singapore Investment Corporation
Pte Ltd
250 North Bridge Road
#38-00 Raffles City Tower
Singapore 179101
Item 2(c). Citizenship
Singapore
Item 2(d). Title of Class of Securities
Common Stock
Item 2(e). CUSIP Number
88337M100
Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or
(c), check whether the person filing is a
N.A.
If this statement is filed pursuant to Rule 13d-1(c), check this box. [x]
<PAGE> 4
Page 4 of 5
Item 4. Ownership
(a) Amount Beneficially owned:1,068,634
(b) Percent of class: 2.05%
(c) Number of shares as to which such person has:
(i) Sole power to vote to direct the vote -- 1,068,634
(ii) Shared power to vote or to direct the vote -- Not applicable
(iii) Sole power to dispose or to direct the disposition of --
1,068,634
(iv) Shared power to dispose or to direct the disposition of --
Not applicable
Item 5. Ownership to Five Percent or Less of a Class
If the statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of
more than five percent of the class of securities, check the following
[X]:
Instruction: Dissolution of a group requires a response to this item.
Item 6. Ownership of More than Five Percent on Behalf of Another Person
Not Applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company
Not Applicable
Item 8. Identification and Classification of Members of the Group
Not Applicable
Item 9. Notice of Dissolution of Group
Not Applicable
Item 10. Certification
Not Applicable
Material to be filed as an Exhibit:
1. Power of Attorney of Government Of Singapore, dated March 5, 1998
(incorporated by reference to Exhibit No. 1 to Schedule 13G, dated March 23,
1998, filed by the Government of Singapore regarding SPDR Trust Series 1).
<PAGE> 5
Page 5 of 5
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
11 FEB 1999 Republic of Singapore
- ----------- By Government of Singapore Investment
Date Corporation Pte Ltd, its attorney-in-fact
by /s/ Seah Wan Hoon
-----------------------------
Seah Wan Hoon
Senior Accountant
